New cancer diagnoses did not rebound as expected following pandemic
Cancer incidence trends in 2021 largely returned to what they were before the COVID-19 pandemic,…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Antidepressant shows promise for treating brain tumours
Drugs that are effective against brain tumours are difficult to find, as many cancer drugs…
Five key factors predict the response of cancer patients to immunotherapy
Immunotherapy has transformed cancer treatment in recent years by enabling the immune system to attack…
ESMO 2024: Breastfeeding after breast cancer is safe
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after…
ESMO 2024: Combination therapy reduced agitated delirium in patients with advanced cancers
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common…
ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer
Studies reported at ESMO 2024 have revealed new groups of women with early-stage (1) and…
ESMO 2024: Coaching programme for increased exercise in breast cancer patients
A study on exercise for cancer patients, presented at ESMO 2024, draws on data from…
ESMO 2024: High dose vitamin D3 does not provide benefit for metastatic colorectal cancer
Data from SOLARIS (Alliance A021703), a multicenter double-blind phase III randomised clinical trial of vitamin…
ESMO 2024: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking…
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
Trastuzumab deruxtecan shows substantial anti-cancer activity in brain metastases in patients with HER2-positive breast cancer…